 Medexus Pharmaceuticals Inc. Medexus or the Company TSXV: MDP, OTCQB: PDDPF today announced that the Company, through its US-based subsidiary, acquired Aptevo BioTherapeutics LLC, a Delaware limited liability company owning the worldwide rights to the commercial hematology asset, IXINITY, from Aptevo Therapeutics, Inc. APVO the Vendor, a biotechnology company focused on developing oncology, autoimmune and hematology therapeutics the Acquisition. IXINITY is an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B a hereditary bleeding disorder characterized by a deficiency of clotting factor IX in the blood, which is necessary to control bleeding. 